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Résumé 
Le lymphome Primaire Osseux de Stade Précoce: une étude 
retrospective multicentrique du Réseau des Cancers Rares 
(Rare Cancer Network, RCN) 
Introduction 
Le lymphome primaire de l'os (LPO) représente moins de 1 % de tous les lymphomes 
malins. Dans cette étude, nous avons évalué le profil de la maladie, les résultats 
thérapeutiques, et les facteurs pronostiques d'une série consécutive de patients 
atteints de LPO de stade 1 et Il. 
Matériel et méthode 
Dans treize institutions du Réseau des Cancers Rares (Rare Cancer Network), 116 
patients ont été traités pour un LPO entre 1987 et 2008, et sont l'objet de cette étude 
rétrospective. Quatre-vingt-sept patients ont subi une chimioradiothérapie (CXRT) 
sans (78), ou avec (9) une chirurgie, 15 ont bénéficié de radiothérapie (RT) sans 
(13), ou avec (2) chirurgie, 14 d'une chimiothérapie (CXT) sans (9), ou avec (5) 
chirurgie. La dose médiane de RT était de 40 Gy (4-60). Le nombre médian de 
cycles de CXT était de 6 (2-8). Le suivi médian était de 41 mois (6-242). 
Résultats 
Le taux de réponse global à la fin du traitement était de 91 % (74% de réponses 
complètes et 17% de réponses partielles). Une récidive locale ou une progression 
ont été observées chez 12 (10%) patients et une récidive systémique chez 17 (15%) 
patients. La survie globale, la survie spécifique, et le contrôle local à 5 ans ont été de 
76%, 78% et 92%, respectivement. En analyse univariée (log-rank test), les facteurs 
pronostiques favorables pour la survie globale et la survie spécifique étaient: un 
indice pronostique international (IPI) inférieur ou égale à 1 (P = 0.009), un grade 
histologique élevé (P = 0.04), une CXRT (P = 0.05), une CXT (P = 0.0004), une 
réponse complète (P <0.0001 ), et une dose de supérieure à 40 Gy (p = 0.005). 
Concernant le contrôle local, seules la rémission complète et stade 1 ont été des 
facteurs favorables. En analyse multivariée, le score IPI, la dose de RT, la rémission 
complète, et la CXT ont influencé le résultat de façon indépendante en ce qui 
concerne la survie globale et la survie spécifique. La rémission complète a été le seul 
facteur prédictif pour le contrôle local. 
Conclusion 
Cette étude multicentrique rétrospective confirme le bon pronostic du LPO de stade 
précoce traité par une combinaison de chimio-radiothérapie. Une dose de suffisant 
de radiothérapie et un nombre adéquat de cycles de chimiothérapie ont été suivis 
des résultats les plus favorables. 
Early Stage Primary Bone Lymphoma: a retrospective, multicenter Rare 
Cancer Network (RCN) study 
Ling Cai, M.D., 1·3 Michael C. Stauder, M.D.,2 Yu-Jing Zhang, M.D.,3 Philip 
Poortmans, M.D., 4 Ye-Xiong Li, M.D.,5 Nicolaos Constantinou, M.D.,6 Juliette 
Thariat, M.D., 7 Sidney P. Kadish, M.D.,8 Tan Dat Nguyen, M.D.,9 Youlia M. Kirova, 
M.D., 10 Pirus Ghadjar, M.D., 11 Damien C. Weber, M.D., 12 Victoria Tuset Bertran, 
M.D.,13 Mahmut Ozsahin, M.D., Ph.D.,1* René-Olivier Mirimanoff, M.0. 1* 
1Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, VD, Switzerland 
2Mayo Clinic, Rochester, MN, USA 
3Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China 
4Verbeeten lnstitute, Tilburg, the Netherlands 
5Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China 
6Theagenio Cancer Hospital, Thessaloniki, Macedonia, Greece 
7 Centre Anti-Cancéreux Antoine-Lacassagne, Nice, Côte d'Azur, France 
8University of Massachusetts Medical School, Worcester, MA, USA 
91nstitut Jean-Godinot, Reims, Champagne-Ardenne, France 
101nstitut Curie, Paris, France 
11 1nselspital, Bern University Hospital, and University of Bern, Switzerland 
12Hôpitaux Universitaires de Genève, Switzerland 
13Hospital Universitari Germans Trias i Pujol, Barcelona, Spain 
Cai.2 
Corresponding Author: 
Prof. René-Oliver Mirimanoff, Centre Hospitalier Universitaire Vaudois, Rue du 
Bugnon 46, 1011, Lausanne, Switzerland, 
Email: Rene-Olivier.Mirimanoff@chuv.ch, 
Tel:+41213144666, Fax: +41213144664 
These authors equally contributed as senior author. 
Conflict of interest: The authors have no conflicts of interest to declare. 
This manuscript has been presented as an oral presentation on November 2, 2010 
at the 52nd Annual Meeting of ASTRO in St Diego. 
Cai.3 
ABSTRACT 
Purpose 
Primary bone lymphoma (PBL) represents less than 1 % of all malignant 
lymphomas. ln this study, we assessed the disease profile, outcome, and 
prognostic factors in patients with stage 1 and 11 PBL. 
Patients and methods 
Thirteen Rare Cancer Network (RCN) institutions enrolled 116 consecutive patients 
with PBL treated between 1987 and 2008 in this study. Eighty-seven patients 
underwent chemoradiotherapy (CXRT) without (78) or with (9) surgery, 15 
radiotherapy (RT) without (13) or with (2) surgery, 14 chemotherapy (CXT) without 
(9) or with (5) surgery. Median RT dose was 40 Gy (range: 4-60). The median 
number of CXT cycles was 6 (range: 2-8). Median follow-up was 41 months (range: 
6-242). 
Results 
The ove ra li response rate at the end of treatment was 91 % (CR 7 4%, PR 17% ). 
Local recurrence or progression was observed in 12 (10%) patients and systemic 
recurrence in 17 (15%). The 5-year overall survival (OS), lymphoma-specific 
survival (LSS), and local contrai (LC) were 76%, 78% and 92%, respectively. ln 
univariate analyses (log-rank test), favorable prognostic factors for OS and LSS 
were International Prognostic Index (IPI) score :51 (P=0.009), high grade histology 
(P=0.04), CXRT (P=0.05), CXT (P=0.0004), CR (P<0.0001), and RT dose> 40 Gy 
(P=0.005). For LC, only CR and stage 1 were favorable factors. ln multivariate 
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analysis, IPI score, RT dose, CR, and CXT were independently influencing the 
outcome (OS and LSS). CR was the only predicting factor for LC. 
Conclusion 
This large multicenter retrospective study confirms the good prognosis of early 
stage PBL treated with combined CXRT. An adequate dose of RT and complete 
CXT regime were associated with better outcome. 
Keywords: Primary bone lymphoma, early stage, radiotherapy, combined treatment 
modality 
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INTRODUCTION 
Primary bone lymphoma (PBL), either in a duits or children [1], is a rare 
presentation of non-Hodgkin's lymphoma, accounting for less than 1 % of all 
malignant lymphomas, for about 5% of all primary malignant bone tumors, and for 
4-5% of all extranodal non-Hodgkin's lymphomas (NHL) [2-4]. PBL was first 
described as a distinct clinical entity by Parker and Jackson in 1939 [5], and 
defined in the 2002 World Health Organization (WHO) classification of tumors of 
soft tissue and bone, as a single skeletal tumor with, or without regional lymph node 
involvement, or multiple bone lesions, without visceral or lymph node involvement 
[6] . 
Almost 90% of PBL patients present with diffuse large B-cell lymphoma histological 
subtype, which may have a better prognosis than that of the less common T-cell 
lymphoma subtype [7-9]. The most commonly affected parts of the skeleton are 
within the metaphysis and diaphysis of the long bones [1 O]. The clinical 
characteristics are non-specific, making a proper diagnosis difficult at the outset. 
Pain, swelling and pathologie fractures are the most common presenting 
symptoms. 
Local radiotherapy (RT) was established as the standard treatment in the 1960's 
with a local relapse rate of around 10-20%, but with a distant relapse rate of about 
50% and a 5-year survival rate ranging between 55-65% [11-13]. The 5-year 
survival rate has been improved to about 70-90% with the addition of 
chemoradiotherapy (CXRT) in early stage disease [11, 14-17]. 
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The role of RT was recently challenged [18, 19], as chemotherapy alone appeared 
to be quite effective, especially with the development of new agents such as 
rituximab. The purpose of our Rare Cancer Network (RCN: 
http//www.rarecancer.net) study was to collect substantial information from a large 
number of patients to more properly define the disease profile, therapeutic 
approach, outcome and prognostic factors of this disease. 
PATIENTS AND METHODS 
Patients 
We collected 116 eligible patients from a total of 136 cases of PBL treated between 
1987 and 2008 in 13 institutions of the RCN. Inclusion criteria included: age > 16 
yrs, confirmed pathological diagnosis of bone involvement, stages 1 and Il 
according to the Ann Arbor staging system [20], and a minimum of 6 months 
follow-up after treatment. After a review of all clinical and pathological records, 20 
cases were excluded from the analysis due to disseminated disease (12 cases) 
and multiple bone involvement (8 cases). Ali the medical records were reviewed for 
age, gender, symptoms, physical examination, laboratory examination, imaging, 
pathological diagnosis, involved sites, stage, International Prognostic Index (IPI) 
[21], treatment modality, response, site of relapse, treatment-related complications, 
time to death, and date of last follow-up. ln this study, ail investigators obtained 
their own lnstitutional Review Board approval for patients' data collection. 
Ali pathology reports were reviewed and "translated" into the WHO classification. 
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The work-up of individual patients included medical history, physical examination, 
complete blood count, lactate dehydrogenase (LDH), erythrocyte sedimentation 
rate (ESR), complete metabolic profile, bone marrow biopsy and plain bone X-ray 
in all patients. Bone computed tomography (CT), magnetic resonance imaging 
(MRI), positron-emission tomography (PET), or whole body CT scan were 
performed according to each institution's policy. Stage was established with the 
Ann Arbor staging system. Single localized bone lesions were classified as stage IE, 
and in case of lymph node involvement on the same side of the diaphragm, patients 
were considered to have stage llE. IPI score was established based on the medical 
records. 
Patients were treated according to each hospital's local policy. The modality of 
treatment included chemotherapy, RT, surgical resection or a combination of these. 
Most patients had a biopsy only (1 OO), however, 16 underwent surgery: 13 had 
some form of local excision or curettage, 2 had a laminectomy with partial excision, 
and 1 had a total hip replacement. 
Response was evaluated according to lymphoma-adapted RECIST [22, 23] 
(Response Evaluation Criteria in Solid Tumors). Early and late treatment toxicities 
were evaluated according to the Common Terminology Criteria for Adverse Events 
(CTCAE) V3.0 [24]. 
Statistical methods 
Overall survival (OS) was calculated from the date of diagnosis to the date of last 
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follow-up or death from any cause. Lymphoma-specific survival (LSS) was 
calculated from the date of diagnosis to the date of lymphoma-related death. Local 
control (LC) was calculated from the date of diagnosis to the date of local 
recurrence. Survival curves were constructed using the Kaplan-Meier method, 
differences were considered significant if the P value wa§.05 (two tailed 
Log-rank test). Multivariate analysis (Cox model) was used to determine the 
independent prognostic factors. Ali prognostic factors identified in the univariate 
analyses with P value < 0.20 were included in the multivariate analyses. 
RESULTS 
Patient and treatment characteristics are presented in Table 1. 
Median age was 51 years (range 17-93 years), and there were 69 males (59%) and 
47 females (41%). 
Majority of patients (75%) received combined CXRT. Treatment sequences were 
chemotherapy followed by radiotherapy (CT-RT) in 64%, radiotherapy followed by 
chemotherapy (RT-CT) in 8%, and concomitant CXRT in 3%. Eighty-eight percent 
received chemotherapy (CXT) in combination or alone. Of these, 68% were treated 
with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or 
CHOP-like chemotherapy, and 32% with rituximab plus CHOP (R-CHOP) 
chemotherapy. 
Response to treatment was evaluated in ail patients. After initial therapy, 74% 
patients had a complete remission (CR), 20% partial remission (PR), 1 % stable 
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disease (SD), and 5% progressive disease (PD). One patient who experienced 
progressive disease, died during salvage treatment. Among patients achieving a 
CR, 81 % were treated with combined CXRT, 10% with RT alone, and 9% with CXT 
alone. 
The 5- and 10- year LC probability was 92% (95% Cl: 86-98) and 80% (95% Cl: 
68-92), respectively. Local failure was observed in 10% of the patients. Of the 7 4% 
patients with CR, 6% had a local relapse, whereas of the 20% of patients who were 
in PR, 30% presented a further local progression (P=0.008). 
Of the patients who received an RT dose of less than 40 Gy, 12% recurred locally, 
versus 8% of those receiving more than 40 Gy (P=0.75). ln the patients with local 
failure, 50% occurred within the planning target volume and 50% outside . 
Distant progression was observed in 15% of the patients after a median time of 7 
months (range 2-72). Thirteen (13%) of the 101 patients who received 
chemotherapy suffered from systemic failure versus 4 (27%) of the 15 patients who 
did not (P=0.23). Thirteen percent of the 67 patients treated with more than 6 
cycles of chemotherapy developed systemic progression, versus 16% of the 49 
patients treated with fewer than 6 cycles (P=O. 79). 
With a median follow-up of 41 months (range 6-242 months ), 63% patients were 
alive without evidence of disease, 12% were alive with disease, 19% patients died 
of lymphoma, and 6% patients died from other causes: 5 from unrelated disease, 
one from lung cancer, one from tonsil cancer. Overall, the 5- and 10-year OS was 
76% (95% Cl: 67-84) and 72% (95% Cl: 61-84), respectively. The 5- and 10-year 
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LSS probability was 78% (95% Cl: 70-86) and 78% (95%CI: 70-86), respectively. 
On univariate analyses, statistically significant factors favorably influencing OS 
were patient age (< 50 years), IPI score 0 or 1 (Figure 1A), RT dose (> 40 Gy) 
(Figure 1 B), high histological grade subtype, combined CXRT, CXT for more than 6 
cycles (Figure 1 C), and CR (Figure 1 D) at the end of treatment. For LSS, the 
above-mentioned parameters (Figure 2A-C), except for age and number of 
chemotherapy cycles, were also favorable factors. RT and stage 1 were favorable 
factors with regard to LC (Figure 20) (Table 2). 
After multivariate analysis, the remaining independent prognostic factors for OS 
and LSS were IPI score < 2, RT dose > 40 Gy, CR, and administration of 
chemotherapy. For LC, CR at completion of treatment remained the only 
independent prognostic factor (Table 3). 
Grade 1-3 leukopenia was observed in 13% patients, grade 1 lymphocytopenia in 
2%, grade 1 thrombocytopenia in 2%. Grade 5 leukopenia occurred in 1 % of 
patients after salvage chemotherapy. Late side effects were rare: grade 1 toxicity in 
3% patients (edema in 3 and pain in 1 ), grade 2 toxicity in 2% patients (myositis in 1 
and osteonecrosis in 1 ), grade 3 toxicity in 3% patients Uoint-effusion in 1, 
osteonecrosis in 1 and pain in 2), grade 4 osteonecrosis in 1 %. The latter patient 
died of a secondary lung cancer. 
DISCUSSION 
To our knowledge, the current study from 13 institutions of the RCN is the second 
largest report on early stage PBL. 
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lt has demonstrated relatively similar patient characteristics compared to other 
published series. A male predominance (male to female: 1.43:1) was found, and 
median age was 51 years, compared to 30-60 years in other series. Pain was the 
most common presenting symptom, followed by a mass or swelling. The most 
common sites of pathological fracture were usually located in the long bones, 
similar to other reports [7, 25]. Like in other reports [26], most of our patients 
presented with Stage IE (ratio between Stage IE and llE: 4:1 ). 
The overall outcome of patients in this study (5-year OS of 76%, LSS of 78%) was 
similar to that found in the literature (5-year OS ranging between 70-90%) [11, 
14-17, 27]. 
Univariate analysis for OS in our study revealed that younger age (< 50 years) 
predicted a better outcome, as reported in other series [11, 26]. Normal LDH level 
was considered to be a favorable prognostic factor in the report of Beal et al [11 ], 
but in our series we could not confirm this observation. Patients with IPI scores 0-1 
had a markedly better outcome compared to those with an IPI score 2-4, as 
previously found by Ramadan et al [4], but not by Alencar et al [27]. ln contrast to 
the study of Ostrowski et al [13] and Horsman et al [26], high grade histology was 
slightly beneficial compared to low grade histology for OS and LSS. Previously 
published papers utilizing SEER database analysis [28] have reported that patients 
with local disease had a better survival than those with extensive disease. However, 
we could not find a significant difference in 5-year OS and LSS between stage 1 and 
Il (78% vs. 67%, P=0.19), which confirms the findings seen in previous series [4, 
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17]. This might be explained by patient selection. Soft tissue involvement was 
observed in 41 % of the patients, and patients with extra-osseous involvement did 
not show a significantly worse outcome in 5-year OS, compared to those without 
extra-osseous involvement (62% vs. 85%, P=0.12). According to some authors, 
soft tissue involvement may just reflect an inflammatory process and not real tumor 
infiltration [29-31]. 
RT was established in the 1960's as the treatment of choice with a high local 
control rate and overall cure rates ranging from 44-63% [11, 27]. However, the role 
of RT alone was challenged over recent years, due to the 50% systemic 
progression rate [11, 30] . Barbieri et al reported that an RT dose of 40 Gy with a 
limited RT volume in combination with CXT seemed to be adequate for local control 
[17]. Our study addressed the issue of RT dose and volume. Radiation of the entire 
bone did not yield a superior outcome compared to partial bone radiation (62% vs. 
70%, P=0.88). However, both univariate and multivariate analyse showed that RT 
dose > 40 Gy was associated with a significantly better 5-year OS and LSS than ::; 
40Gy (95% vs. 66%, P=0.0054, and 95% vs. 69%, respectively) and a 
non-significant trend towards a better local control (96% vs. 89%, P=0.32). 
CXRT already demonstrated its superiority compared to single therapeutic 
approaches with 5-year OS between 60-90% in recent studies [11, 16, 31-33]. 
lnterestingly, Alencar et al [27] recently reported no benefit with CXRT. Although 
there is no consensus regarding the optimal timing between either RT or 
chemotherapy, chemotherapy followed by RT was suggested to be the standard 
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approach [34]. 
With the advent of highly effective chemotherapy, the raie of RT has been 
questioned by some authors. ln advanced-stage disease, Ramadan et al found that 
patients who received chemotherapy and RT had a worse outcome compared to 
those who received chemotherapy alone [4]. ln the SWOG 8736 study update 
which was on non-PBL lymphoma, there was no difference between CXRT and 
chemotherapy alone [18, 19]. Similar results were reported in some studies [11, 35, 
36], and also in a report on children [37]. Rituximab is now used in association with 
CHOP or a CHOP-like regimen in the treatment of lymphoma, and studies have 
demonstrated its positive impact on survival [38]. ln our series, the proportion of 
patients treated with R-CHOP was lower (3:7) than with CHOP alone, and we could 
not find any significant differences in survival between the two regimens. 
Acute side effects were moderate. Leukopenia was the most common early toxicity 
following chemotherapy. The only reported late toxicity cases involved a limited 
occurrence of osteonecrosis. 
ln conclusion, early stage PBL has a fairly good prognosis. Local contrai is 
excellent, and systemic failure occurs infrequently. Young age(< 50) and a good IPI 
score(< 2) were positive prognostic factors at diagnosis. The raie of chemotherapy 
is central in the treatment of PBL. Chemotherapy followed by RT is superior for OS 
and LSS to a sequence of radiotherapy followed by chemotherapy. Although 
chemotherapy was superior to radiotherapy alone, radiotherapy still plays a raie in 
local contrai. An RT dose of more than 40 Gy, and more than 6 chemotherapy 
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cycles are associated with a better outcome. Although our results need to be 
interpreted with caution because of a relatively limited follow up (41 months) and its 
retrospective nature, we feel that our findings are important, especially because it is 
unlikely that a prospective study will be done, given how rare this cancer is. 
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Figure legends 
Figure 1. Univariate analyses for prognostic factors on overall survival (OS). 
a) OS according to international prognostic index (IPI) score; IPI 0, 1 
improved survival compared with IPI ~ 2 (P=0.009). 
b) OS according to radiotherapy (RT) dose; RT dose > 40 Gy improved 
survival compared with RT dose :5 40 Gy (P=0.0054). 
c) OS according to chemotherapy (CXT) cycles; CXT cycles~ 6 improved 
survival compared with CXT cycles <6 (P=0.01 ). 
d) OS according to response rate; patients with complete response (CR) 
improved survival compared with those without CR (P<0.0001 ). 
Figure 2. Univariate analyses for prognostic factors on lymphoma-specific 
survival (LSS) and local contrai (LC). 
a) LSS according to radiotherapy (RT) dose; RT dose > 40 Gy improved 
LSS compared with RT dose :5 40 Gy (P=0.02). 
b) LSS according to chemoradiotherapy (CXRT); patients with CXRT 
improved LSS compared with those without CXRT (P=0.01 ). 
c) LSS according to response rate; patients with complete response (CR) 
improved LSS compared with those without CR (P<0.0001 ). 
d) LC according to response rate; patients with complete response (CR) 
improved LC compared with those without CR. 
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Table1. Clinical and treatment characteristics of patients 
Parameter Patients (N) % 
Clinical characteristics 
Median age (50) 
;§ 50 63 54 
> 50 53 46 
Gender 
M 69 59 
F 47 41 
Histology subtype 
Diffuse large B cell 91 78 
Follicular B cell 7 6 
Anaplastie large cell 6 5 
Other 12 11 
Histological grade 
High 100 86 
lntermediate 7 6 
Low 9 8 
Stage 
Stage IE 93 80 
Stage llE 23 20 
Initial symptoms 
Pain 106 91 
Mass/swelling 46 40 
Neurological symptoms 28 24 
Pathological fracture 20 17 
B symptoms 20 17 
LDH level 
Normal 70 60 
High 30 26 
Not done 16 14 
Site involved 
Spi ne 33 28 
Pelvis 23 20 
Femur 16 14 
Face bone 15 13 
Humerus 12 10 
Other sites 17 15 
IPI score 
:o;1 81 70 
>2 35 30 
Treatment characteristics 
Combined treatment and sequence 
CTRT 74 64 
RTCT 9 8 
Concomitant CXRT 4 3 
CXT alone 14 12 
RT alone 15 13 
Chemotherapy regimens 
R-CHOP 32 28 
CHOP or CHOP-like 69 60 
NoCXT 15 12 
Treatment modality with surgery 
Yes 16 14 
No 100 86 
Abbreviations: LDH=lactate dehydrogenase; 1 Pl=international prognostic index; CT-RT=chemotherapy 
followed by radiotherapy; RT-CT=radiotherapy followed by chemotherapy; CXRT=combined 
chemoradiotherapy; CXT=chemotherapy; RT=radiotherapy; CHOP=cyclophosphamide,doxorubicin, 
vincristine, and prednisone ; R-CHOP=rituximab with CHOP 
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Table 2. Unîvariate analyses (Log-Rank test) 
Variable N 5-y 95% p 5-y 95% p 5-y 95%CI p 
os Cl LSS Cl LC(%) 
(%) (%) 
Ali patients 116 76 67-85 78 70-86 92 86-98 
Age 
<50 57 86 76-96 0.008 86 76-96 0.09 94 87-101 0.99 
~50 59 67 53-81 71 58-84 90 81-99 
Gender 
Fern ale 47 72 58-86 0.18 74 60-88 0.10 93 85-101 0.38 
Male 69 79 67-91 81 70-92 91 84-98 
IPI score 
;::2 34 59 40-78 0.009 64 46-82 0.02 93 83-103 0.62 
<2 82 84 75-93 85 76-94 91 84-98 
Histologîcal grade 
hîgh 100 78 69-87 0.04 80 71-89 0.05 92 86-98 0.26 
M/L 16 64 38-90 64 38-90 90 73-107 
Clînical symptoms 
B symptoms 
Yes 20 62 36-88 0.22 62 36-88 0.13 92 76-108 0.38 
No 96 78 69-88 81 72-90 92 86-98 
Pathological fracture 
Cai.23 
Yes 20 76 54-98 0.94 85 79-101 0.76 94 83-105 0.94 
No 96 76 66-86 77 67-87 91 85-97 
LDH level 
High 30 93 83-103 0.10 93 83-103 0.17 83 68-98 0.10 
Normal 70 72 60-84 75 64-86 93 86-100 
ND 16 72 48-96 72 48-96 100 100 
Extra-osseous involvement 
Yes 48 62 46-78 0.12 68 52-84 0.06 93 85-101 0.81 
No 68 85 76-94 85 76-94 91 83-99 
Stage ( Ann Arbor) 
IE 93 78 69-88 0.19 81 72-90 0.13 92 86-98 0.04 
llE 23 67 43-91 67 43-91 90 77-103 
Treatment modality 
CXRT 87 79 69-89 0.001 81 72-90 <0.001 93 87-99 0.13 
CXT 14 92 78-106 92 78-106 77 54-1 OO 
RT 15 49 22-76 49 22-76 100 100 
CXRT vs. RT&CXT 
CXRT 87 79 69-89 0.05 81 72-90 0.01 93 87-99 0.66 
RT&CXT 29 69 51-87 69 51-87 87 73-101 
Treatment modality of CXRT&RT vs. CXT 
CXRT&RT 102 75 66-84 0.27 94 89-99 0.08 94 89-99 0.08 
CXT 14 92 78-106 77 54-100 77 4-100 
Cai.24 
Treatment modality of CXRT &CXT vs. RT 
CXRT&CXT 101 80 71-89 0.004 82 73-91 <0.0001 91 85-97 0.24 
RT 15 49 22-76 49 22-76 100 100 
Subgroup for CXRT vs.CXT alone 
CXRT 87 79 69-89 0.47 81 72-90 0.63 93 87-99 0.12 
CXT 14 92 78-106 92 78-106 77 54-1 OO 
Subgroup for CXRT sequence ( not including the 4 concomitant cases ) 
CT-RT 74 83 72-94 0.001 86 77-95 0.0006 95 89-101 0.02 
RT-CT 9 39 6-72 39 6-72 78 51-105 
R-CHOP chemoradiotherapy (RCXRT) vs. CHOP or CHOP-like chemoradiotherapy (CCXRT) 
RCXRT 23 89 74-104 0.11 89 74-104 0.04 93 80-106 0.87 
CCXRT 64 77 66-88 80 69-91 93 86-1 OO 
No CXRT 29 69 51-87 69 51-97 87 73-101 
CXT regimen comparison (R-CHOP vs. CHOP vs. No CXT) 
R-CHOP 32 81 63-99 0.002 81 63-99 <0.0001 88 75-101 0.27 
CHOP 69 80 69-91 83 73-93 92 85-99 
NoCXT 15 49 22-76 49 22-76 100 100 
Subgroup for RCXRT vs. CCXRT 
RCXRT 23 89 74-104 0.41 89 74-104 0.56 93 80-106 0.57 
CCXRT 64 77 66-88 80 69-91 93 80-100 
Subgroup for comparison within CXT regimens ( R-CHOP vs. CHOP or CHOP-like) 
R-CHOP 32 81 63-99 0.84 81 63-99 0.92 88 75-101 0.27 
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CHOP 69 80 69-91 83 64-102 92 88-99 
Cycles of CXT 
<6 49 69 55-83 0.01 75 62-88 0.06 88 77-99 0.87 
è::6 67 81 70-92 81 70-92 93 87-99 
RT dose 
>40 Gy 39 95 88-102 0.0054 95 88-102 0.02 96 89-103 0.32 
::; 40 77 66 54-78 69 57-81 89 81-97 
RT treatment volume (partial bone vs. entire bone) 
Partial 60 77 65-89 0.54 79 68-90 0.65 91 82-1 OO 0.18 
Entire 42 74 59-89 76 62-90 97 90-104 
No RT 14 92 78-106 92 78-106 77 54-1 OO 
Response Group ( CR vs. No CR) 
CR 86 84 75-93 <0.0001 87 79-95 <0.0001 96 91-101 <0.0001 
No CR 30 51 28-74 51 28-74 79 62-96 
Abbreviations: OS=overall survival; LSS=lymphoma-specific survival; LC=local contrai; 
IPl=international prognostic index; M/L=lntermediate/low; LDH=lactate dehydrogenase; ND=not 
done; CXRT=chemoradiotherapy; RT=radiotherapy; CXT=chemotherapy; CT-RT=chemotherapy 
followed by radiotherapy; RT-CT=radiotherapy followed by chemotherapy; 
CHOP=cyclophosphamide,doxorubicin, vincristine, and prednisone; R-CHOP=rituximab plus CHOP; 
RCXRT=RCHOP regimen with chemoradiotherapy CCXRT=CHOP regimen with 
chemoradiotherapy; CR=complete response. 
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Table 3. Multivariate analyses 
os LSS LC 
Variable 
RR p RR p RR p 
IPI score (<2) 1.68 0.014 1.73 0.02 NS 
RT dose (>40 Gy) 1.97 0.005 1.72 0.05 NS 
Response (CR) 2.17 0.0004 2.56 <0.0001 2.96 0.00 
CXT (Yes) 2.46 0.0002 2.91 <0.0001 NS 
Abbreviations: OS=overall survival; LSS=lymphoma-specific survival; LC=local contrai; RR=risk 
ratio; IPl=international prognostic index; RT=radiotherapy; CR=complete response; 
CXT=chemotherapy; NS=no significant. 
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